Neurology-Focused Alector Downgraded On Failed Alzheimer’s Study, BofA Securities Highlights Lack Of Catalysts

Alector’s AL002 misses primary endpoint in Alzheimer’s trial. BofA downgrades stock, cuts price target, and highlights near-term challenges. Latest Ratings for ALEC Date Firm Action From To Mar 2022 Stifel Downgrades Buy Hold Feb 2022 Citigroup Maintains Buy Sep 2021 William Blair Initiates Coverage On Outperform View More Analyst Ratings for ALEC View the Latest…

Read More